Trial Outcomes & Findings for Digital Clinical Hypnosis for Chronic Pain Management (NCT NCT06050083)
NCT ID: NCT06050083
Last Updated: 2026-01-06
Results Overview
Total # of hypnosis sessions listened to by participants
COMPLETED
NA
100 participants
During the 8 weeks of study participation
2026-01-06
Participant Flow
Primarily recruited from Research Match and the UW Rehabilitation Medicine Participant Pool.
Participant milestones
| Measure |
Study 1: 8 Week Treatment
Participants that had access to the Rose application for 8 weeks.
|
Study 1: 4 Week Waitlist
4 Week Waitlist (4 weeks waitlist, then 4 weeks of Rose application access)
|
Study 2: 8 Week Treatment
Participants had access to the Rose application for 8 weeks.
|
Study 2: 4 Week Waitlist
4 Week Waitlist (4 weeks waitlist, then 4 weeks of Rose application access)
|
|---|---|---|---|---|
|
Overall Study
STARTED
|
26
|
24
|
26
|
24
|
|
Overall Study
COMPLETED
|
26
|
24
|
26
|
24
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Digital Clinical Hypnosis for Chronic Pain Management
Baseline characteristics by cohort
| Measure |
Study 1: 8 Week Treatment
n=26 Participants
Participants that had access to the Rose application for 8 weeks.
|
Study 1: 4 Week Waitlist
n=24 Participants
Participants that had access to the Rose application for 4 weeks (8 weeks total participation = 4 weeks waitlist with no access to the Rose application, then 4 weeks of access)
|
Study 2: 8 Week Treatment
n=26 Participants
Participants had access to the Rose application for 8 weeks
|
Study 2: 4 Week Waitlist
n=24 Participants
Participants that had access to the Rose application for 4 weeks (8 weeks total participation = 4 weeks waitlist with no access to the Rose application, then 4 weeks of access)
|
Total
n=100 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|
|
Sex/Gender, Customized
Sex at Birth · Female
|
19 Participants
n=37 Participants
|
18 Participants
n=56 Participants
|
12 Participants
n=82 Participants
|
12 Participants
n=31 Participants
|
61 Participants
n=5 Participants
|
|
Sex/Gender, Customized
Sex at Birth · Male
|
7 Participants
n=37 Participants
|
6 Participants
n=56 Participants
|
14 Participants
n=82 Participants
|
12 Participants
n=31 Participants
|
39 Participants
n=5 Participants
|
|
Sex/Gender, Customized
Gender · Female
|
19 Participants
n=37 Participants
|
17 Participants
n=56 Participants
|
11 Participants
n=82 Participants
|
12 Participants
n=31 Participants
|
59 Participants
n=5 Participants
|
|
Sex/Gender, Customized
Gender · Male
|
7 Participants
n=37 Participants
|
6 Participants
n=56 Participants
|
12 Participants
n=82 Participants
|
12 Participants
n=31 Participants
|
37 Participants
n=5 Participants
|
|
Sex/Gender, Customized
Gender · Transgender
|
0 Participants
n=37 Participants
|
1 Participants
n=56 Participants
|
2 Participants
n=82 Participants
|
0 Participants
n=31 Participants
|
3 Participants
n=5 Participants
|
|
Sex/Gender, Customized
Gender · Non-binary
|
0 Participants
n=37 Participants
|
0 Participants
n=56 Participants
|
1 Participants
n=82 Participants
|
0 Participants
n=31 Participants
|
1 Participants
n=5 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
6 Participants
n=37 Participants
|
5 Participants
n=56 Participants
|
1 Participants
n=82 Participants
|
3 Participants
n=31 Participants
|
15 Participants
n=5 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
19 Participants
n=37 Participants
|
19 Participants
n=56 Participants
|
25 Participants
n=82 Participants
|
21 Participants
n=31 Participants
|
84 Participants
n=5 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
1 Participants
n=37 Participants
|
0 Participants
n=56 Participants
|
0 Participants
n=82 Participants
|
0 Participants
n=31 Participants
|
1 Participants
n=5 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
2 Participants
n=37 Participants
|
1 Participants
n=56 Participants
|
0 Participants
n=82 Participants
|
0 Participants
n=31 Participants
|
3 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Asian
|
1 Participants
n=37 Participants
|
1 Participants
n=56 Participants
|
1 Participants
n=82 Participants
|
0 Participants
n=31 Participants
|
3 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=37 Participants
|
0 Participants
n=56 Participants
|
0 Participants
n=82 Participants
|
0 Participants
n=31 Participants
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Black or African American
|
9 Participants
n=37 Participants
|
7 Participants
n=56 Participants
|
15 Participants
n=82 Participants
|
13 Participants
n=31 Participants
|
44 Participants
n=5 Participants
|
|
Race (NIH/OMB)
White
|
10 Participants
n=37 Participants
|
11 Participants
n=56 Participants
|
8 Participants
n=82 Participants
|
10 Participants
n=31 Participants
|
39 Participants
n=5 Participants
|
|
Race (NIH/OMB)
More than one race
|
4 Participants
n=37 Participants
|
3 Participants
n=56 Participants
|
2 Participants
n=82 Participants
|
1 Participants
n=31 Participants
|
10 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=37 Participants
|
1 Participants
n=56 Participants
|
0 Participants
n=82 Participants
|
0 Participants
n=31 Participants
|
1 Participants
n=5 Participants
|
|
Region of Enrollment
United States
|
26 Participants
n=37 Participants
|
24 Participants
n=56 Participants
|
26 Participants
n=82 Participants
|
24 Participants
n=31 Participants
|
100 Participants
n=5 Participants
|
|
Years of Education
High School Graduate/GED
|
2 Participants
n=37 Participants
|
2 Participants
n=56 Participants
|
1 Participants
n=82 Participants
|
1 Participants
n=31 Participants
|
6 Participants
n=5 Participants
|
|
Years of Education
Some college or vocational school
|
10 Participants
n=37 Participants
|
11 Participants
n=56 Participants
|
2 Participants
n=82 Participants
|
5 Participants
n=31 Participants
|
28 Participants
n=5 Participants
|
|
Years of Education
2 year college graduate
|
5 Participants
n=37 Participants
|
4 Participants
n=56 Participants
|
3 Participants
n=82 Participants
|
0 Participants
n=31 Participants
|
12 Participants
n=5 Participants
|
|
Years of Education
4 year college graduate
|
3 Participants
n=37 Participants
|
6 Participants
n=56 Participants
|
7 Participants
n=82 Participants
|
3 Participants
n=31 Participants
|
19 Participants
n=5 Participants
|
|
Years of Education
Graduate school
|
6 Participants
n=37 Participants
|
1 Participants
n=56 Participants
|
13 Participants
n=82 Participants
|
15 Participants
n=31 Participants
|
35 Participants
n=5 Participants
|
|
Age, Continuous
|
48.3 Years
STANDARD_DEVIATION 20.8 • n=37 Participants
|
49.5 Years
STANDARD_DEVIATION 15.6 • n=56 Participants
|
38.6 Years
STANDARD_DEVIATION 12.7 • n=82 Participants
|
40.6 Years
STANDARD_DEVIATION 16.7 • n=31 Participants
|
48.9 Years
STANDARD_DEVIATION 18.3 • n=5 Participants
|
PRIMARY outcome
Timeframe: During the 8 weeks of study participationPopulation: The number of hypnosis sessions listened to was prespecified to be aggregated for all participants because (1) it was over the entire course of the 8-week study and participants in both arms had access and (2) the key variable of interest for feasibility was any difference in the number and rate of listening as a function of session duration (and not differences as a function of condition, as those in the waitlist condition would by default listen to fewer sessions).
Total # of hypnosis sessions listened to by participants
Outcome measures
| Measure |
Study 1
n=50 Participants
Summary scores for all participants in both the Treatment/Control groups for Study 1.
|
Study 2
n=50 Participants
Summary scores for all participants in both the Treatment/Control groups for Study 2.
|
Study 2: 8 Week Treatment
Participants had access to the Rose application for 8 weeks.
|
Study 2: 4 Week Waitlist
4 Week Waitlist (4 weeks waitlist, then 4 weeks of Rose application access)
|
|---|---|---|---|---|
|
Frequency of Using Rose Application
10 minute audio recording
|
64 # of hypnosis sessions listened to
|
134 # of hypnosis sessions listened to
|
—
|
—
|
|
Frequency of Using Rose Application
20 minute audio recording
|
220 # of hypnosis sessions listened to
|
274 # of hypnosis sessions listened to
|
—
|
—
|
|
Frequency of Using Rose Application
5 minute audio recording
|
81 # of hypnosis sessions listened to
|
79 # of hypnosis sessions listened to
|
—
|
—
|
PRIMARY outcome
Timeframe: 8 week assessmentPopulation: The number of participants who expressed expressed am interest in continued interest access to the application was prespecified to be aggregated for all participants because the milestone for this feasibility variable was the overall rate of interest in for those who used the application at least once, collapsed across condition. We were not interested in, or anticipated, any between-group difference in this variable.
Participants reporting how interested they would be in continuing to use the Rose application: "If the Rose web/phone application were available to download, how interested would you be in downloading and using this application?" 4 - Extremely interested 3 - Very interested 2 - Somewhat interested 1 - Little interested 0 - Not interested
Outcome measures
| Measure |
Study 1
n=50 Participants
Summary scores for all participants in both the Treatment/Control groups for Study 1.
|
Study 2
n=50 Participants
Summary scores for all participants in both the Treatment/Control groups for Study 2.
|
Study 2: 8 Week Treatment
Participants had access to the Rose application for 8 weeks.
|
Study 2: 4 Week Waitlist
4 Week Waitlist (4 weeks waitlist, then 4 weeks of Rose application access)
|
|---|---|---|---|---|
|
Continued Interest in Using Rose Application
|
2.5 Score on a scale
Standard Deviation 1.3
|
2.8 Score on a scale
Standard Deviation 1.5
|
—
|
—
|
PRIMARY outcome
Timeframe: 8 week assessmentPopulation: The number of participants who expressed a willingness to pay fo continued access to the application was prespecified to be aggregated for all participants because the milestone for this feasibility variable was the overall rate of willingness to pay for the application for those who used the application at least once, collapsed across condition. We were not interested in, or anticipated, any between-group difference in this variable.
Participants that reported a willingness to pay for continued access to the Rose application (results available for Study 2 only): "Would you be willing to pay some amount for a monthly subscription to Rose, to have continued access?" 1 - Yes 0 - No
Outcome measures
| Measure |
Study 1
n=17 Participants
Summary scores for all participants in both the Treatment/Control groups for Study 1.
|
Study 2
Summary scores for all participants in both the Treatment/Control groups for Study 2.
|
Study 2: 8 Week Treatment
Participants had access to the Rose application for 8 weeks.
|
Study 2: 4 Week Waitlist
4 Week Waitlist (4 weeks waitlist, then 4 weeks of Rose application access)
|
|---|---|---|---|---|
|
Willingness to Pay for Continued Use of Rose Application
|
11 Participants
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: 4 Week, 8 Week timepointsPopulation: The number of participants who expressed satisfaction will using the application was prespecified to be aggregated for all participants because the milestone for this feasibility variable was the overall rates of the satisfaction ratings for those who used the application at least once (i.e., participants in both conditions), collapsed across condition. We were not interested in, or anticipated, any between-group difference in this variable.
Participants answered a Global Satisfaction question about their satisfaction with using the Rose application "Taking all things into account, how satisfied are you with using the Rose web application?" 4 - Very Satisfied 3 - Somewhat Satisfied 2 - Neutral 1 - Somewhat Dissatisfied 0 - Very Dissatisfied
Outcome measures
| Measure |
Study 1
n=50 Participants
Summary scores for all participants in both the Treatment/Control groups for Study 1.
|
Study 2
n=50 Participants
Summary scores for all participants in both the Treatment/Control groups for Study 2.
|
Study 2: 8 Week Treatment
Participants had access to the Rose application for 8 weeks.
|
Study 2: 4 Week Waitlist
4 Week Waitlist (4 weeks waitlist, then 4 weeks of Rose application access)
|
|---|---|---|---|---|
|
Participant Satisfaction
|
2.8 Score on a scale
Standard Deviation 0.9
|
3.4 Score on a scale
Standard Deviation 0.9
|
—
|
—
|
PRIMARY outcome
Timeframe: 8 Week TimepointPopulation: The system usability scores for those who used the application at least once were prespecified to be aggregated for all participants because participants in both conditions had access to the application. The feasibility milestone was overall system usability score in participants in both conditions. The two groups had access the same application, and therefore we were not interested in, or anticipated, any between-group difference in this variable.
Scale title: System Usability Scale. Minimum - Maximum range: 0 to 100. Higher scores indicate more usability (ease of use). There are no subscale scores for this measure.
Outcome measures
| Measure |
Study 1
n=50 Participants
Summary scores for all participants in both the Treatment/Control groups for Study 1.
|
Study 2
n=50 Participants
Summary scores for all participants in both the Treatment/Control groups for Study 2.
|
Study 2: 8 Week Treatment
Participants had access to the Rose application for 8 weeks.
|
Study 2: 4 Week Waitlist
4 Week Waitlist (4 weeks waitlist, then 4 weeks of Rose application access)
|
|---|---|---|---|---|
|
System Usability Scale (SUS)
|
80.33 Score on a scale
Standard Deviation 16.05
|
87.31 Score on a scale
Standard Deviation 12.72
|
—
|
—
|
SECONDARY outcome
Timeframe: Baseline, 4 Weeks, 8 WeeksA 0-10 Numerical Rating scale of average pain in the past week: "Please rate your pain by choosing the one number that best describes your pain at its WORST in the PAST WEEK, where 0 is "no pain" and 10 is "pain as bad as you can imagine"
Outcome measures
| Measure |
Study 1
n=26 Participants
Summary scores for all participants in both the Treatment/Control groups for Study 1.
|
Study 2
n=24 Participants
Summary scores for all participants in both the Treatment/Control groups for Study 2.
|
Study 2: 8 Week Treatment
n=26 Participants
Participants had access to the Rose application for 8 weeks.
|
Study 2: 4 Week Waitlist
n=24 Participants
4 Week Waitlist (4 weeks waitlist, then 4 weeks of Rose application access)
|
|---|---|---|---|---|
|
Average Pain - Past Week
Baseline
|
5.81 Score on a scale
Standard Deviation 1.44
|
5.71 Score on a scale
Standard Deviation 1.88
|
5.92 Score on a scale
Standard Deviation 1.70
|
5.83 Score on a scale
Standard Deviation 1.83
|
|
Average Pain - Past Week
4 Weeks
|
5.69 Score on a scale
Standard Deviation 1.74
|
5.42 Score on a scale
Standard Deviation 1.79
|
5.04 Score on a scale
Standard Deviation 1.51
|
5.17 Score on a scale
Standard Deviation 1.49
|
|
Average Pain - Past Week
8 Weeks
|
5.38 Score on a scale
Standard Deviation 2.12
|
4.96 Score on a scale
Standard Deviation 1.72
|
4.46 Score on a scale
Standard Deviation 1.84
|
3.46 Score on a scale
Standard Deviation 2.08
|
SECONDARY outcome
Timeframe: Baseline, 4 Weeks, 8 WeeksA 0-10 Numerical Rating scale of worst pain in the past week: "Please rate your pain by choosing the one number that best describes your pain at its WORST in the PAST WEEK, where 0 is "no pain" and 10 is "pain as bad as you can imagine"
Outcome measures
| Measure |
Study 1
n=26 Participants
Summary scores for all participants in both the Treatment/Control groups for Study 1.
|
Study 2
n=24 Participants
Summary scores for all participants in both the Treatment/Control groups for Study 2.
|
Study 2: 8 Week Treatment
n=26 Participants
Participants had access to the Rose application for 8 weeks.
|
Study 2: 4 Week Waitlist
n=24 Participants
4 Week Waitlist (4 weeks waitlist, then 4 weeks of Rose application access)
|
|---|---|---|---|---|
|
Worst Pain - Past Week
4 Weeks
|
7.19 Score on a scale
Standard Deviation 1.60
|
6.92 Score on a scale
Standard Deviation 1.47
|
6.16 Score on a scale
Standard Deviation 1.57
|
6.63 Score on a scale
Standard Deviation 1.35
|
|
Worst Pain - Past Week
8 Weeks
|
6.69 Score on a scale
Standard Deviation 1.91
|
6.91 Score on a scale
Standard Deviation 1.81
|
5.73 Score on a scale
Standard Deviation 2.39
|
4.96 Score on a scale
Standard Deviation 2.39
|
|
Worst Pain - Past Week
Baseline
|
7.23 Score on a scale
Standard Deviation 1.34
|
7.63 Score on a scale
Standard Deviation 1.38
|
7.35 Score on a scale
Standard Deviation 1.02
|
7.29 Score on a scale
Standard Deviation 0.95
|
SECONDARY outcome
Timeframe: Baseline (week 0), 4 week assessment, 8 week assessmentDomain assessed: Sleep Disturbance. Ratings are summed and converted to T scores (Mean = 50 and SD = 10 in the normative sample). Higher scores indicate more sleep disturbance. Scores that are \>= 55 (i.e., one half a SD above the normative mean) are considered clinically elevated.
Outcome measures
| Measure |
Study 1
n=26 Participants
Summary scores for all participants in both the Treatment/Control groups for Study 1.
|
Study 2
n=24 Participants
Summary scores for all participants in both the Treatment/Control groups for Study 2.
|
Study 2: 8 Week Treatment
n=26 Participants
Participants had access to the Rose application for 8 weeks.
|
Study 2: 4 Week Waitlist
n=24 Participants
4 Week Waitlist (4 weeks waitlist, then 4 weeks of Rose application access)
|
|---|---|---|---|---|
|
PROMIS Sleep Disturbance Short Form 8a
Baseline
|
57.3 T-score
Standard Deviation 7.9
|
58.5 T-score
Standard Deviation 8.7
|
55.2 T-score
Standard Deviation 7.4
|
57.2 T-score
Standard Deviation 9.5
|
|
PROMIS Sleep Disturbance Short Form 8a
4 Weeks
|
58.4 T-score
Standard Deviation 9.7
|
57.3 T-score
Standard Deviation 9.1
|
41.7 T-score
Standard Deviation 10.7
|
54.0 T-score
Standard Deviation 10.2
|
|
PROMIS Sleep Disturbance Short Form 8a
8 Weeks
|
57.1 T-score
Standard Deviation 10.0
|
53.5 T-score
Standard Deviation 10.8
|
50.5 T-score
Standard Deviation 10.6
|
50.0 T-score
Standard Deviation 12.6
|
SECONDARY outcome
Timeframe: Baseline (week 0), 4 week assessment, 8 week assessmentDomain assessed: Pain interference. Ratings are summed and converted to T scores (Mean = 50 and SD = 10 in the normative sample). Higher scores indicate more pain interference. Scores that are \>= 55 (i.e., one half a SD above the normative mean) are considered clinically elevated.
Outcome measures
| Measure |
Study 1
n=26 Participants
Summary scores for all participants in both the Treatment/Control groups for Study 1.
|
Study 2
n=24 Participants
Summary scores for all participants in both the Treatment/Control groups for Study 2.
|
Study 2: 8 Week Treatment
n=26 Participants
Participants had access to the Rose application for 8 weeks.
|
Study 2: 4 Week Waitlist
n=24 Participants
4 Week Waitlist (4 weeks waitlist, then 4 weeks of Rose application access)
|
|---|---|---|---|---|
|
PROMIS Pain Interference Short Form
Baseline
|
64.3 Score on a scale
Standard Deviation 6.7
|
64.4 Score on a scale
Standard Deviation 7.2
|
60.5 Score on a scale
Standard Deviation 5.3
|
61.0 Score on a scale
Standard Deviation 4.59
|
|
PROMIS Pain Interference Short Form
4 Weeks
|
64.4 Score on a scale
Standard Deviation 6.4
|
64.9 Score on a scale
Standard Deviation 7.2
|
59.4 Score on a scale
Standard Deviation 5.3
|
61.0 Score on a scale
Standard Deviation 5.9
|
|
PROMIS Pain Interference Short Form
8 Weeks
|
64.0 Score on a scale
Standard Deviation 9.0
|
61.7 Score on a scale
Standard Deviation 7.6
|
56.6 Score on a scale
Standard Deviation 8.7
|
56.1 Score on a scale
Standard Deviation 9.1
|
SECONDARY outcome
Timeframe: Baseline (week 0), 4 week assessment, 8 week assessmentDomain assessed: Anxiety. Ratings are summed and converted to T scores (Mean = 50 and SD = 10 in the normative sample). Higher scores indicate more anxiety. Scores that are \>= 55 (i.e., one half a SD above the normative mean) are considered clinically elevated.
Outcome measures
| Measure |
Study 1
n=26 Participants
Summary scores for all participants in both the Treatment/Control groups for Study 1.
|
Study 2
n=24 Participants
Summary scores for all participants in both the Treatment/Control groups for Study 2.
|
Study 2: 8 Week Treatment
n=26 Participants
Participants had access to the Rose application for 8 weeks.
|
Study 2: 4 Week Waitlist
n=24 Participants
4 Week Waitlist (4 weeks waitlist, then 4 weeks of Rose application access)
|
|---|---|---|---|---|
|
PROMIS Anxiety Short Form 7a
Baseline
|
58.0 T-score
Standard Deviation 10.5
|
55.5 T-score
Standard Deviation 10.9
|
57.8 T-score
Standard Deviation 4.8
|
54.0 T-score
Standard Deviation 7.4
|
|
PROMIS Anxiety Short Form 7a
4 Weeks
|
60.4 T-score
Standard Deviation 11.3
|
59.2 T-score
Standard Deviation 13.7
|
57.4 T-score
Standard Deviation 6.7
|
54.8 T-score
Standard Deviation 9.6
|
|
PROMIS Anxiety Short Form 7a
8 Weeks
|
58.2 T-score
Standard Deviation 11.3
|
57.0 T-score
Standard Deviation 12.4
|
55.4 T-score
Standard Deviation 8.0
|
54.1 T-score
Standard Deviation 10.2
|
SECONDARY outcome
Timeframe: Baseline (week 0), 4 week assessment, 8 week assessmentDomain assessed: Opioid Use How assessed: Single item asking participants to indicate whether or not they currently using any opioid mediations. Unit of measure is the number and rate of participants who indicated that they are currently using at least one opioid medication.
Outcome measures
| Measure |
Study 1
n=26 Participants
Summary scores for all participants in both the Treatment/Control groups for Study 1.
|
Study 2
n=24 Participants
Summary scores for all participants in both the Treatment/Control groups for Study 2.
|
Study 2: 8 Week Treatment
n=26 Participants
Participants had access to the Rose application for 8 weeks.
|
Study 2: 4 Week Waitlist
n=24 Participants
4 Week Waitlist (4 weeks waitlist, then 4 weeks of Rose application access)
|
|---|---|---|---|---|
|
Number of Participants Using Opioids
|
10 Participants
|
2 Participants
|
1 Participants
|
2 Participants
|
Adverse Events
Study 1: 8 Week Treatment
Study 1: 4 Week Waitlist
Study 2: 8 Week Treatment
Study 2: 4 Week Waitlist
Serious adverse events
Adverse event data not reported
Other adverse events
| Measure |
Study 1: 8 Week Treatment
n=26 participants at risk
Participants that had access to the Rose application for 8 weeks.
|
Study 1: 4 Week Waitlist
n=24 participants at risk
Participants that had access to the Rose application for 4 weeks (8 weeks total participation = 4 weeks waitlist with no access to the Rose application, then 4 weeks of access)
|
Study 2: 8 Week Treatment
n=26 participants at risk
Participants had access to the Rose application for 8 weeks
|
Study 2: 4 Week Waitlist
n=24 participants at risk
Participants that had access to the Rose application for 4 weeks (8 weeks total participation = 4 weeks waitlist with no access to the Rose application, then 4 weeks of access)
|
|---|---|---|---|---|
|
Musculoskeletal and connective tissue disorders
Muscle Strain
|
3.8%
1/26 • Enrollment until the 8 week follow up timepoint
Adverse Events were systematically assessed by including the following question at all survey timepoints: "Have you experienced any negative side effects since our last contact as a result of the study (Yes/No)". IF YES: Please specify the negative side effects. Participants could also self-report Adverse Events when receiving a survey reminder phone call from a staff coordinator.
|
0.00%
0/24 • Enrollment until the 8 week follow up timepoint
Adverse Events were systematically assessed by including the following question at all survey timepoints: "Have you experienced any negative side effects since our last contact as a result of the study (Yes/No)". IF YES: Please specify the negative side effects. Participants could also self-report Adverse Events when receiving a survey reminder phone call from a staff coordinator.
|
0.00%
0/26 • Enrollment until the 8 week follow up timepoint
Adverse Events were systematically assessed by including the following question at all survey timepoints: "Have you experienced any negative side effects since our last contact as a result of the study (Yes/No)". IF YES: Please specify the negative side effects. Participants could also self-report Adverse Events when receiving a survey reminder phone call from a staff coordinator.
|
0.00%
0/24 • Enrollment until the 8 week follow up timepoint
Adverse Events were systematically assessed by including the following question at all survey timepoints: "Have you experienced any negative side effects since our last contact as a result of the study (Yes/No)". IF YES: Please specify the negative side effects. Participants could also self-report Adverse Events when receiving a survey reminder phone call from a staff coordinator.
|
Additional Information
Dr. Mark Jensen, PhD, Principal Investigator
University of Washington
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place